The catalogue is somebody else's design
Set this seller's product rail beside another one reviewed here and the two are the same object with different numbers in it: the same lane order, the same product-tag vocabulary, the same needle-free oral dissolving tablet lane described in the same terms.
That is not an accusation. Both brands are almost certainly built on the same telehealth platform, and dozens of apparently independent GLP-1 brands are — the same clinical practice and the same platform vendor recur across a dozen of the sellers we read in this batch alone.
What it costs a reader is the assumption that brand variety means market variety. Two brands with different names, different founders and different marketing may be the same catalogue, the same prescribing network and the same pharmacy, priced differently. That is worth knowing before treating a shortlist of five brands as five options.
Three lanes, and a promotional bar
The rail prices a compounded semaglutide, a compounded tirzepatide and a needle-free oral dissolving tablet, each as a from figure. Twenty-seven of the one hundred and fifty-eight sellers here price an oral route.
A promotional bar offering a stated amount off select weight-loss plans rides the same page, so the first figure a new buyer pays is not the published one. No plan term appears beside any of the three.
The identity disclosure is good
The privacy policy names the operating company three times, once with a street address, and states in its own words that the company is a technology platform, is not a medical practice or a pharmacy, and does not practise medicine, prescribe or dispense.
That is a clean division of responsibility and better than most. What it leaves is a gap on the other side: no compounding pharmacy is named, no individual clinician is named, and no service area is published. One hundred and twenty-six of the one hundred and fifty-eight sellers here name no pharmacy and one hundred and fifteen publish no service area.
Luma Meds's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $139.99/mofrom, per month; a $50-off promotional bar on select weight-loss plans rides the same page | September 2026source |
| Tirzepatide (compounded) | $166/mofrom, per month, in the same catalogue rail | September 2026source |
| Semaglutide (compounded-oral) | $232/mofrom, per month, for the needle-free ODT lane in the same catalogue rail | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Luma Meds's current price →Good fit if
- Readers who want to see how similar two apparently unrelated brands can be when they share a platform.
- Buyers who want a needle-free oral dissolving tablet priced beside two injections.
- People who want a plain statement of what the company they are buying from does and does not do.
Look elsewhere if
- Anyone building a shortlist who assumes different brands mean different supply chains.
- Readers who need a plan term beside a price; none of the three carries one.
- Buyers who want the compounding pharmacy or a clinician named, or a service-area list.
How this review was verified
- Re-read the privacy policy, which carries the full product rail, on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Compared this seller's catalogue rail against another seller's added in the same batch, lane by lane and tag by tag, and recorded the match as a shared platform rather than as a claim about ownership.
- Read the operating company off three separate occurrences in the privacy policy, including one with a street address.
- Recorded the promotional bar as a condition on the published figures rather than as a price.
- Screened the operating entity and both spellings of the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. None returned a letter. Untitled letters are published separately and were not searched.